

Brno Oncology Days
Nursing Conference

Conference Programme

1–3 November 2023
Brno, Exhibition Centre, Hall E



www.onkologickedny.cz/en



NETWORKING BRINGS PROFESSIONALS TOGETHER

Join us in Brno and network with your colleagues, interact with key opinion leaders, ask questions and debate on burning topics in the field of medical oncology in a uniquely meaningful way.

See you at BOD 2024
23–25 October 2024

CONTENT

Introduction	4
Conference plan	6

CONFERENCE PROGRAMME

THURSDAY / J. BAKEŠ HALL

International Brno Oncology Day	
Thoracic Surgery	11
Breast Cancer (BOD + IBOD)	11
Breast Cancer	12
Molecular Tumour Board	12

FRIDAY / J. BAKEŠ HALL

International Brno Oncology Day	
Clinical Research	13
Breaking News in Oncology 2023	13
Update on the Treatment of Gastrointestinal Tumours.....	13
Meet the Experts	14

INVITED SPEAKERS

Rupert Bartsch	15
Dukagjin M. Blakaj	16
Dorota Gabryś	17
Axel Grothey	18
Florian Lordick.....	19
Michal Mego	20
Csaba Polgár	21
Gerald Prager	22
Rafal Tarnawski.....	23
Eva Vegh.....	24
Christoph Benedikt Westphalen.....	25
Ya-Jung Cheng.....	26
József Furák	27

Mong-Wei Lin.....	28
Ramón Rami-Porta.....	29
Zsolt Szabo	30
Marcin Zieliński.....	31
Alied van der Aa-van Delden.....	32
Trish Bartley	33



INTRODUCTION

Dear colleagues, dear friends,

On behalf of the Masaryk Memorial Cancer Institute and the Organizing Committee, we would like to **welcome you to the 47th Brno Oncology Days and the 37th Nursing Conference**. The Brno Oncology Days is the **largest national professional event with an international dimension, involving** all professions dealing with oncological issues.

Last year, we welcomed 1,985 participants, including 24 invited foreign speakers, in the traditional premises of the Congress Centre in Hall E at the Brno Exhibition Centre. During the three-day conference, 373 papers were presented, and a total of 331 oral presentations were given in 45 educational sessions and 12 free communication sessions.

This year, the Brno Oncology Days are traditionally opened with the **Glio Meeting, a multidisciplinary meeting of brain tumor experts**, followed by **PharmAround** workshop on clinical trials and an educational seminars for **general practitioners and non-oncologists** interested in the oncology field.

In addition to the traditional educational sessions focused on breast cancer, lung cancer, gastrointestinal and genitourinary tract tumors, immunotherapy, targeted therapy, surgical oncology or palliative care, the programme for professionals also includes special sessions dedi-

cated to precision oncology and molecular tumor board activities, preventive medicine and germ cell tumors. It newly features the Psychological Care in the Medical Context conference and an international programme section dedicated to chest tumors and prepared in cooperation with the University Hospital Brno.

Moreover, we have been organizing the **International Brno Oncology Days (I-BOD)** for three years in a row, taking place on 2–3 November 2023. The International Brno Oncology Days aims to deepen cooperation between specialists in the Central European region. This year, our invitation was accepted by a number of **leading experts**, as well as **young physicians and scientists** from neighboring countries, including university centers in **Vienna, Budapest, Bratislava and Leipzig**. The multifarious programme offers a wide range of symposia, from educational sessions informing about news from the ASCO and ESMO international conferences to the **Meet the Experts** case reports session. We firmly believe that creative and welcoming academic environment, which we are striving to create, will be a breeding ground for developing collaboration not only between experts in their field, but also between the next generation of young physicians and translational and clinical research experts.

Nevertheless, the Nursing Conference programme also offers attractive topics. We would like to highlight a window of innovations in imaging and therapeutic methods as well as the present and future

of preventive programmes in the Czech Republic. As for professional development, there is a programme session dedicated to educational and working differences in registered nurses among European countries. Also included are popular workshops aimed at improving practical skills.

We are delighted that many professional societies have accepted the patronage of the Brno Oncology Days and the Nursing Conference as well as **ESMO** and **The Czech Society for Oncology (ČOS)** being our guarantors again.

We are always pleased that participants can enjoy our conferences as being both highly professional and enjoyable social events, being a place where they can meet their colleagues and friends. Our firm belief is that this will be the case again this year. In addition to Wednesday's opening ceremony, we will also welcome distinguished guests from the I-BOD. On Thursday, a **gala evening** will take place at the OREA Congress Hotel, with an award ceremony and books launch.

Last but not least, we would like to express our profound gratitude to all sponsors and exhibitors for their financial support, without which an event of this magnitude would not have been possible.

In closing, we would like to wish the conference success while looking forward to your participation.



A handwritten signature in black ink.

Radka Lordick Obermannová, MD, PhD
Chair of BOD and IBOD programme



A handwritten signature in black ink.

PhDr. Jana Kocourková, MBA
Chair of Nursing Conference programme



A handwritten signature in black ink.



Prof. Marek Svoboda, MD, PhD
General Director of Masaryk Memorial Cancer Institute

BRNO EXHIBITION CENTRE



Brno, Krížkovského street, hall E





WEDNESDAY – 1 November 2023

	BRNO ONCOLOGY DAYS					
	J. Bakeš Hall	J. Šprindrich Hall	R. Werner Hall	L. Bakešová Hall	V. Morávek Hall	Lounge S2
OPENING CEREMONY (13.30–14.00)						
14.00–15.30	PharmAround / CzECRIN Workshop	Glio Meeting 2023 I	Educational Session Renal Carcinoma: From Diagnosis to Treatment 2023	Educational Session Management of Immunotherapy Toxicity	Educational Symposium for General Practitioners and Non-oncologists I	Translational Cancer Research in Practice
COFFEE BREAK (15.30–15.45)						
15.45–17.15	Educational Session Ovarian Cancer	Glio Meeting 2023 II	Educational Session Prostate Cancer	Educational Session Palliative Care	Educational Symposium for General Practitioners and Non-oncologists II	
DINNER (17.15–17.30)						
17.30–19.00	Satellite Symposium Novartis (17.30–18.30)	Satellite Symposium BMS (17.30–18.30)	Surgical Oncology (open communication)		Educational Symposium for General Practitioners and Non-oncologists III	
END OF THE FIRST DAY (19.00)						

THURSDAY – 2 November 2023

	BRNO ONCOLOGY DAYS (BOD and IBOD)			
	J. Bakeš Hall	J. Šprindrich Hall	R. Werner Hall	L. Bakešová Hall
7.30–8.30		Satellite Symposium Eli Lilly	Satellite Symposium Gilead	Radiotherapy (open communication)
COFFEE BREAK (8.30–8.45)				
8.45–10.15	IBOD Thoracic Surgery	Educational Session Breast Cancer	Educational Session Prevention and Early Cancer Detection	Advances in Systemic Treatment (open communication)
BREAK (10.15–10.30)				
10.30–12.00	IBOD + BOD Breast Cancer Keynote lecture: Prof. Polgár	Educational Session Pneumooncology	Educational Session Cancer Data and Informatics	Varia (open communication)
12.00–12.30	Keynote lecture: Trish Bartley	LUNCH (12.00–13.00)		
13.00–14.00	Satellite Symposium Servier	Satellite Symposium Novartis	Satellite Symposium MSD	
BREAK (14.00–14.15)				
14.15–15.45	IBOD Breast Cancer	Cardiotoxicity and Cardioprotection in Radiotherapy (open communication)	Surgical Oncology – Rectal Cancer (open communication)	
COFFEE BREAK (15.45–16.00)				
16.00–17.30	IBOD Molecular Tumour Board	Educational Session Locally Advanced Pancreatic Cancer	Transplantation in Solid Tumour Oncology (open communication)	
BREAK (17.30–17.45)				
17.45–18.45	Satellite Symposium Roche	Satellite Symposium Astra Zeneca	Case Reports (open communication)	
GALA DINNER WITH CONTESTS WINNERS AND BOOKS LAUNCHING (19.30–24.00)				

FRIDAY – 3 November 2023

	BRNO ONCOLOGY DAYS (BOD and IBOD)		
	J. Bakeš Hall	J. Šprindrich Hall	R. Werner Hall
7.30–8.30	IBOD Clinical Research	Educational Symposium of Nutritional Working Group in Oncology	
BREAK (8.30–8.40)			
8.40–10.10	IBOD Breaking News in Oncology 2023	Gastrointestinal Tumours (open communication)	Psychological Care in the Medical Context I (8.00–10.00)
COFFEE BREAK (10.10–10.25)			
10.25–11.55	IBOD Update on the Treatment of Gastrointestinal Tumours	Head and Neck Tumours (open communication)	Psychological Care in the Medical Context II (10.15–11.45)
BREAK (11.55–12.05)			
12.05–13.35	IBOD Meet the Experts (Young Oncologists Programme)	Educational Session Patients with germ cell cancer - do they have a different prognosis? Do we treat them differently?	Psychological Care in the Medical Context III (12.00–13.30)
LUNCH (13.35–14.30)			

J. BAKEŠ HALL / THURSDAY 2 NOVEMBER 2023

8:45–10:15	IBOD THORACIC SURGERY Moderator: T. Horváth (Brno) Chairs: M. Zielinski, Z. Szabo, M. Lin, Y. Cheng, J. Furák, R. Rami-Porta (Zakopane, Szeged, Taipei, Barcelona)	10:30–12:00	IBOD + BOD BREAST CANCER Chairs: C. Polgár, T. Rutkowski, M. Palácová, M. Krásenská (Budapest, Gliwice, Brno)
8:45	FINE-TUNING SURGICAL ONCOLOGY BY MERATS TRIAL T. Horváth (Brno)	10:30	ACCELERATED PARTIAL BREAST IRRADIATION USING INTERSTITIAL MULTICATHETER BRACHYTHERAPY COMPARED WITH WHOLE-BREAST IRRADIATION FOR EARLY BREAST CANCER – 10-YEAR RESULTS OF THE GEC-ESTRO PHASE 3, NON-INFERIORITY TRIAL (Keynote Lecture) C. Polgár, V. Strnad, O. Ott et al. (Budapest, Erlangen, Leipzig)
8:56	TRANSCERVICAL LOBECTOMY M. Zielinski (Zakopane)	10:50	PREOPERATIVE BREAST CANCER RADIOTHERAPY COMBINED WITH SYSTEMIC THERAPY D. Gabryś (Gliwice)
9:07	SPONTANEOUS VENTILATION WITH DOUBLE LUMEN TUBE INTUBATION IS MISSION IMPOSSIBLE! OR IS IT STILL POSSIBLE? Z. Szabo (Szeged)	11:05	TWENTY YEARS AND 2,000 PATIENTS LATER – INTRAOPERATIVE RADIOTHERAPY: EXPERIENCE Ż. Kaniszewska Dorsz (Gliwice)
9:18	ROLE OF ANAESTHESIOLOGY IN LUNG CANCER PROGRAMME IN NATIONAL TAIWAN UNIVERSITY CANCER CENTER Y. Cheng (Taipei)	11:20	DO WE KNOW HOW TO TREAT OLDER HER2 POSITIVE BREAST CANCER PATIENTS? I. Kolářová (Hradec Králové)
9:29	ROLE OF SURGERY IN LUNG CANCER PROGRAMME AT NTU CANCER CENTER M. Lin (Taipei)	11:30	MONITORING ESTRADIOL LEVELS DURING LHRH ANALOGUE AND TAMOXIFEN TREATMENT M. Krásenská (Brno)
9:40	SPONTANEOUS VENTILATION THORACIC SURGERY. EUROPEAN VIEW J. Furák (Szeged)	11:40	NEW DATA FROM THE BRESKA REGISTER M. Palácová, M. Zimovjanová, B. Donociková, M. Protivánková (Brno, Praha, Olomouc)
9:51	THE IASLC LUNG CANCER STAGING PROJECT – TOWARDS THE 9TH EDITION OF THE TNM CLASSIFICATION R. Rami-Porta (Barcelona)	11:50	Discussion
10:02	Discussion	12:05–12:25	KEYNOTE LECTURE: WHAT DOES MINDFULNESS OFFER PEOPLE WITH CANCER? Chairs: M. Světlák, T. Bartley (Brno, Bicester)
10:15	Break	12:05	WHAT DOES MINDFULNESS OFFER PEOPLE WITH CANCER? A KEYNOTE PRESENTATION BASED ON THE PRINCIPLES OF MINDFULNESS-BASED COGNITIVE THERAPY FOR CANCER (MBCT-CA) T. Bartley (Bicester)
		12:25	Lunch

14:15–15:45 IBOD BREAST CANCER

Chairs: M. Holánek, ě. Věgh, E. Létalová, R. Bartsch
(Brno, Budapest, Vienna)

- 14:15 Opening
- 14:20 **NEW TRENDS IN THE TREATMENT OF HORMONE RECEPTOR-POSITIVE BREAST CANCER**
ě. Věgh (Budapest)
- 14:40 **TRIPLE NEGATIVE BREAST CANCER – NEW TRENDS IN TREATMENT**
R. Bartsch (Vienna)
- 15:00 **CURRENT TREATMENT OPTIONS IN HER2 POSITIVE BREAST CANCER**
M. Holánek (Brno)
- 15:20 **DISCUSSION ABOUT A CASE REPORT**
E. Létalová (Brno)
- 15:45 Coffee break

16:00–17:30 IBOD MOLECULAR TUMOUR BOARD

Chairs: P. Grell, Ľ. Křížová, C. Westphalen, A. Grothey
(Brno, Praha, Munich, Memphis)

- 16:00 Opening
- 16:05 **INTEGRATIVE PRECISION ONCOLOGY – BUILDING SUSTAINABLE STRUCTURES FOR THE FUTURE**
C. Westphalen (Munich)
- 16:25 **PILOT RESULTS FROM THE NATIONAL MOLECULAR TUMOUR BOARD REGISTRY GENESIS**
P. Grell (Brno)
- 16:45 **TUMOUR MUTATION BURDEN (UN)RELIABLE BIOMARKER**
Ľ. Křížová (Praha)
- 17:05 **HOW TO READ THE RESULTS OF THE COMPLEX GENOMIC PROFILING**
A. Grothey (Memphis)
- 17:25 Discussion
- 17:30 Break

J. BAKEŠ HALL / FRIDAY 3 NOVEMBER 2023

7:30–8:30	IBOD CLINICAL RESEARCH Chairs: L. Hernychová, P. Müller (Brno)	8:55	HYPOFRACTIONATED RT AND IMMUNOTHERAPY IN RECURRENT/PERSISTENT HEAD AND NECK CANCER PATIENTS D. Blakaj (Ohio)
7:30	CIRCULATING TUMOR DNA CORRELATES WITH LACTATE DEHYDROGENASE, CYFRA 21-1, AND CRP LEVELS IN PATIENTS WITH ADVANCED NSCLC M. Svatoň, M. Burešová, L. Benešová, M. Minarik, P. Hošek, J. Baxa, M. Pešek, O. Fiala, R. Ptáčková, T. Hálková (Plzeň, Praha)	9:10	GENITOURINARY TUMOURS M. Mego (Bratislava)
7:40	PACLITAXEL NEUROPATHY – A GLYCOPROTEOMIC APPROACH TO PREDICTIVE BIOMARKERS IN BREAST CANCER A. Urminský, L. Hernychová, J. Halámková, T. Henek (Brno)	9:25	NEUROENDOCRINE TUMOURS B. Bencsiková (Brno)
7:50	AGING AND BIOMARKERS AT CANCER PATIENTS L. Hruška, P. Borský, H. Párová, D. Holmannová, L. Borská, M. Vošmik (Hradec Králové)	9:45	GYNECOLOGIC TUMOURS R. Tarnawski (Gliwice)
8:00	LOCAL TREATMENT OF IPSILATERAL BREAST RECURRENCES – 5-YEAR RESULTS OF A COMPARATIVE ANALYSIS OF ALTERNATIVE THERAPEUTIC OPTION V. Smanyakó, N. Mészáros, T. Major, C. Polgár (Budapest)	10:00	Discussion
8:10	COMBINED TREATMENT OF REFRACTORY AND RELAPSED PEDIATRIC TUMORS USING A DENDRITIC CELL VACCINE K. Polášková, M. Kýr, P. Múdry, D. Valík, L. Zdražilová Dubská, K. Černá Pilátová, J. Štěrba (Brno)	10:10	Coffee break
8:20	Discussion	10:25–11:55	IBOD UPDATE ON THE TREATMENT OF GASTROINTESTINAL TUMOURS Chairs: F. Lordick, G. Prager, A. Grothey, A. Ryška, I. Kiss (Leipzig, Vienna, Memphis, Hradec Králové, Brno)
8:30	Break	10:25	Opening
8:40–10:10	IBOD BREAKING NEWS IN ONCOLOGY 2023 Chairs: R. Lordick Obermannová, R. Bartsch, M. Mego, D. Blakaj, B. Bencsiková, R. Tarnawski (Brno, Vienna, Bratislava, Ohio, Gliwice)	10:30	MOLECULAR CHARACTERIZATION AS A PREREQUISITE FOR THE TREATMENT OF GASTROINTESTINAL CANCERS A. Ryška (Hradec Králové)
8:40	BREAST CANCER R. Bartsch (Vienna)	10:45	UPPER GI TUMOURS F. Lordick (Leipzig)
		11:05	BILIARY TRACT TUMOURS I. Kiss (Brno)
		11:20	PANCREATIC CANCER G. Prager (Vienna)
		11:35	COLORECTAL CANCER A. Grothey (Memphis)
		11:55	Break

J. BAKEŠ HALL / FRIDAY 3 NOVEMBER 2023

12:05–13:35 IBOD MEET THE EXPERTS

(Young Oncologists Programme)

Moderators: R. Lordick Obermannová, R. Němeček,
B. Bystrický

Chairs: M. Loveček, V. Jedlička, R. Lohynská,
G. Prager, F. Lordick, A. Grothey, I. Kiss,
B. Mohelníková-Duchoňová (Brno, Trenčín, Olomouc,
Praha, Vienna, Leipzig, Memphis)

- 12:05 Opening
- 12:10 **LOCALLY ADVANCED OESOPHAGEAL CANCER –
CASE REPORT**
M. Bischof (Leipzig)
- 12:30 **LOCALLY ADVANCED PANCREATIC CANCER/
OLIGOMETASTATIC DISEASE – CASE REPORT**
A. Langer (Olomouc)
- 12:50 **LOCALLY ADVANCED RECTAL CANCER – CASE
REPORT**
R. Szöllösi (Budapest)
- 13:10 **METASTATIC COLON CANCER – CASE REPORT**
N. Pazderová (Bratislava)
- 13:30 Closing
- 13:35 Lunch





Assoc. Prof. Rupert Bartsch, MD

Medical University of Vienna, Austria

TRIPLE NEGATIVE BREAST CANCER – NEW TRENDS IN TREATMENT

Thursday 02.11.2023, 2:40 p.m., J. Bakeš Hall

BREAKING NEWS IN BREAST CANCER

Friday 03.11.2023, 8:40 a.m., J. Bakeš Hall

Rupert Bartsch is an associate professor of medicine at the Medical University of Vienna, Vienna, Austria, and serves as the director of the Breast Cancer Programme at the Department of Oncology. Prior to this, he was head of the breast centre at the Elisabethinen Hospital in Linz, Austria, and was temporarily based at the German Breast Group in Neu Isenburg, Germany. Rupert Bartsch has a longstanding clinical and scientific focus on breast cancer and brain metastases.

Together with his colleagues, he has published over 150 articles in peer-reviewed journals, among them *Nature Medicine*, *Lancet Oncology*, *Journal of Clinical Oncology*, *Annals of Oncology* and *Clinical Cancer Research*.

Selected recent papers:

1. Müller V, Bartsch R, Lin NU, Montemurro F, Pegram MD, Tolaney SM. Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review. *Cancer Treat Rev* 2023; 115: 102527.
2. Welsch E, Schuster E, Krainer M, Marhold M, Bartsch R et al. Comparison of RNA Marker Panels for Circulating Tumor Cells and Evaluation of Their Prognostic Relevance in Breast Cancer. *Cancers (Basel)* 2023; 15(4): 1271.
3. Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. *Nat Med* 2022; 28(9): 1840–1847.

4. Bolliger M, Lanmüller P, Schuetz M, Heilig B, Windischbauer A ... Bartsch R et al. The iTOP trial: Comparing immediate techniques of oncoplastic surgery with conventional breast surgery in women with breast cancer – A prospective, controlled, single-center study. *Int J Surg* 2022; 104: 106694.

5. Zhou Q, Gampenrieder SP, Frantal S, Rinnerthaler G, Singer CF, Egle D, Pfeiler G, Bartsch R et al. Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. *Clin Cancer Res* 2022; 28(4): 697–707.

6. Deutschmann C, Bartsch R, Singer CF, Gschwantler-Kaulich D, Seifert M et al. Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria. *BMC Cancer* 2022; 22(1): 1099.

7. Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ ... Bartsch R et al. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. *Cancer Treat Rev* 2022; 111: 102468.

On the occasion of Brno Oncology Days, Assoc. Prof. Bartsch will deliver an invited lectures on the topic “Triple negative breast cancer – new trends in treatment” and “Breaking news in breast cancer”.



Assoc. Prof. Dukagjin M. Blakaj MD, PhD

Radiation Oncology Department, Ohio State University Comprehensive Cancer Center, USA

HYPOFRACTIONATED RT AND IMMUNOTHERAPY IN RECURRENT/PERSISTENT HEAD AND NECK CANCER PATIENTS

Friday 03.11.2023, 8:55 a.m., J. Bakeš Hall

Dukagjin M. Blakaj MD, PhD., an Associate Professor, Clinical Director, H&N/Skull base Division Director in the Radiation Oncology department at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He leads a busy clinical practice in H&N, skin, skull base and spine malignancies and also leads the Spine division. He is also the H&N-Intraoperative and CNS/Pediatric fellowship director within the radiation oncology department. Dr. Blakaj earned his bachelors and master's in molecular Biophysics & Biochemistry and Chemistry from Wesleyan University; Biochemistry M.S, Biochemistry Ph.D. and MD from Albert Einstein College of Medicine. He is on national committees for H&N/skin cancer clinical trials including NCI, ECOG and NRG. His Ph.D. thesis centered on the molecular, biochemical, biophysical, immune and cellular research exploring protein-ligand interactions based on the papillomavirus transcription factor, E2. At the James Cancer Center, his research interests continue to be clinical and translational in nature with his goal being to tailor cancer treatments to patients based on their molecular profiles of treatment resistance and conduct research that will ultimately lead to novel clinical trials, especially in identifying molecular biomarkers for overall treatment response and immunotherapy response in H&N/Skull Base cancers.

He is a PI on a multi-PI H&N Immunotherapy and IORT clinical trial as well as a prospective spine stereotactic radiosurgery clinical trial. He has been published in over seventy-five research articles. He has been a faculty member at The Ohio State University for ten years and recently became the clinical director within the Radiation Oncology Department.

Selected recent papers:

1. Bonomi M, Blakaj DM, Kabarriti R, Colvett K, Takiar V et al. PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy. *Int J Radiat Oncol Biol Phys* 2023; 116(3): 551–559.
2. Zhang L, Judd RT, Zhao S, Rygalski C, Li M, Briody A, Swendseid B, Blakaj DM et al. Immediate resection of positive margins improves local control in oral tongue cancer. *Oral Oncol* 2023; 141: 106402.
3. Baliga S, Yildiz VO, Bazan J, Palmer JD, Jhavar SR, Konieczkowski DJ, Grecula J, Blakaj DM, et al. Disparities in Survival Outcomes among Racial/Ethnic Minorities with Head and Neck Squamous Cell Cancer in the United States. *Cancers (Basel)* 2023; 15(6): 1781.
4. Gillison ML, Ferris RL, Harris J, Colevas AD, Mell LK, Kong C, ... Blakaj DM et al. Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504. *Int J Radiat Oncol Biol Phys* 2023; 115(4): 847–860.

On the occasion of Brno Oncology Days, Assoc. Prof. Blakaj will deliver an invited lecture on the topic “Hypofractionated RT and immunotherapy in recurrent/persistent head and neck cancer patients”.



Prof. Dorota Gabryś, MD, PhD.

MSC National Research Institute of Oncology in Gliwice, Poland

PREOPERATIVE BREAST CANCER RADIOTHERAPY COMBINED WITH SYSTEMIC THERAPY

Thursday 02.11.2023, 10:50 a.m., J. Bakeš Hall

Dorota Gabryś, MD, PhD, in Radiation Oncology is working at MSC National Research Institute of Oncology in Gliwice, Poland as Professor. Besides her medical degree she also got her MSc in Radiation Biology at UCL London, UK. She performed research in Tumour Microcirculation Group, at Gray Cancer Institute in London, UK, in Medical Faculty CGC, University of Technology Dresden, and PET Center Dresden-Rossendorf, Research Center Dresden-Rossendorf, Germany.

Her research programme as a radiation oncologist is dedicated to providing best breast cancer radiotherapy in patients treated in postoperative settings as well as in advanced inoperable cases, and as a boost in preoperative setting in combination with immunotherapy (Ongoing project Breast BOOSTER). She also performed investigations into the radiation induce heart disease in breast cancer patients as well as in animals' studies.

Moreover, her research interest is in improving outcomes for patients with metastatic disease treated with stereotactic cranial and extracranial radiotherapy and outcomes of radiotherapy in prostate cancer patients.

She received ESTRO Accuray Clinical Award in 2011. She is a member of the Clinical Committee, National Societies Committee of the ESTRO, Breast Cancer Guidelines Committee as well as Polish societies PTRO, PTOK (chairwoman of Silesian Branch of PTO, and PTBR).

Selected recent papers:

1. Franco P, De Felice F, Kaidar-Person O, Gabryś D, Marta GN, et al. Equity, Diversity, and Inclusion in Radiation Oncology: A Bibliometric Analysis and Critical Review. *Int J Radiat Oncol Biol Phys* 2023; 116(2): 232–245.
2. Mametov R, Sagandykova G, Monedeiro-Milanowski M, Gabryś D, Pomastowski P. Electropolymerized polypyrrole-MOF composite as a coating material for SPME fiber for extraction VOCs liberated by bacteria. *Sci Rep* 2023; 13(1): 8933.
3. Kubeczko M, Jarzab M, Krzywon A ... Gabryś D. Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases. *J Clin Med* 2023; 12(5): 2044.
4. Kubeczko M, Gabryś D, Gawkowska M, Polakiewicz-Gilowska A, Cortez AJ et al. Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer. *Cancers (Basel)* 2023; 15(3): 690.

On the occasion of Brno Oncology Days, Prof. Gabryś will deliver an invited lecture on the topic "Preoperative breast cancer radiotherapy combined with systemic therapy".



Axel Grothey, MD

West Cancer Center and Research Institute, Memphis, Tennessee, USA

HOW TO READ THE RESULTS OF THE COMPLEX GENOMIC PROFILING

Thursday 02.11.2023, 5.05 p.m., J. Bakeš Hall

UPDATE ON THE TREATMENT OF COLORECTAL CANCER

Friday 03.11.2023, 11.35 a.m., J. Bakeš Hall

Axel Grothey, MD, is a medical oncologist and Director of Gastrointestinal Cancer Research at West Cancer Center and Research Institute, in Germantown.

Dr. Grothey received his medical degree at Ruhr-Universität Bochum, Germany, and completed residencies at West German Tumor Center and the Institute of Pathology at the University of Essen and a residency and fellowship at the University of Bochum. He also completed a research fellowship at MD Anderson Cancer Center at the University of Texas. He joined Mayo Clinic as a consultant in 2005 and was appointed as Professor of Oncology in 2007. He left Mayo Clinic in summer of 2018 to join West Cancer Center.

Dr. Grothey's clinical interests focus on gastrointestinal cancers, in particular colorectal cancer, novel therapeutics, precision medicine, and clinical trial design and statistics. As an investigator, his research has been funded by the National Cancer Institute (NCI) and the National Institutes of Health, among other organizations. He co-chaired the NCI Gastrointestinal Cancer Steering Committee for 4 years until 2021 after having served as chair of the NCI Colon Cancer Task Force for 6 years. Until June 2018 he was vice chair of the Gastrointestinal Cancer Committee of the Alliance for Clinical Trials in Oncology, an NCI-funded cooperative group. He is also chaired the Academic and Community Cancer Research United international research network based at Mayo Clinic until he joined West Cancer Center.

He currently holds professional positions in the Association of German Internists, German Cancer Association, Working Group of Experimental Cancer Research in Germany, American Association for Cancer Research, European Association for Cancer Research, American Society for Cell Biology, MD Anderson Associates, American Society of Clinical Oncology, European Society for Medical Oncology, German Association for Internal Oncology, and the Minnesota Medical Association.

Until 2018, Dr. Grothey was member of the NCCN Guidelines Committee for Colon, Rectal, and Anal Cancer. He is a member of the European Society of Medical Oncology (ESMO) guidelines committee for colorectal cancer.

Dr. Grothey performs journal review and editorial activities for numerous medical journals and is a member of the editorial board of Journal of the National Cancer Institute. In educational activities, he is a six-time recipient of Teacher of the Year recognition at Mayo Clinic. Dr. Grothey has given numerous international, national, and regional presentations, as well as invited and visiting professor presentations. He has co-authored more than 600 articles, books, book chapters, editorials, abstracts, and letters.

Selected recent papers:

1. Ducreux M, Tabernero J, Grothey A et al. Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer. *Eur J Cancer* 2023; 184: 137–150.

2. Seeber A, Battaglin F, Zimmer K ... Grothey A et al. Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer. *Clin Cancer Res* 2022; 28(9): 1863–1870.

On the occasion of Brno Oncology Days, Dr. Grothey will deliver an invited lectures on the topic “How to read the results of the complex genomic profiling” and “Update on the treatment of colorectal cancer”.



Prof. Florian Lordick, MD, PhD

University Cancer Center Leipzig (UCCL), Leipzig University Medical Center, Leipzig, Germany

NOVEL APPROACHES FOR HER 2 POSITIVE AND CLAUDIN 18.2 POSITIVE UPPER GI TUMOURS

Friday 03.11.2023, 10:45 a.m., J. Bakeš Hall

Florian Lordick is a Full Professor of Medicine at the University of Leipzig, Germany. He was appointed as director of the University Cancer Center Leipzig in 2012, which, in collaboration with the University of Jena Medical Center, recently was awarded as one of 15 German Oncology Centers of Excellence and receives funding from the German Cancer Aid. He also is head of the Department of Medicine (oncology, gastroenterology, hepatology, and pulmonology) at the University of Leipzig Medical Center.

Dr. Lordick's scientific focus is on clinical and translational research in immuno-oncology and targeted treatment of cancer, with a specific focus on gastrointestinal tract tumours. He has a great interest in multimodality treatment of GI cancers, in personalized medicine and in survivorship topics. His research is funded by the German Cancer Aid, the German Ministry of Education and Research and by the European Commission.

Dr. Lordick has authored and co-authored more than 400 peer-reviewed and PubMed-listed articles. Dr. Lordick served as Director of Education at the European Society for Medical Oncology (ESMO) from 2019–2022, as president of the International Gastric Cancer Association (IGCA) and he is a former member of the executive board of the German Cancer Society and former chair of the EORTC Gastrointestinal Tract Cancer Working groups.

He holds reviewer and advisory roles at various research funding organizations and European comprehensive cancer centers including Masaryk Memorial Cancer Center in Brno, Czech Republic. He also is the newly appointed Editor-in-Chief of ESMO Gastrointestinal Oncology, official scientific journal of the European Society for Medical Oncology.

Selected recent papers:

1. Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. *Lancet* 2023; 401(10389): 1655–1668.
2. Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. *Nat Med* 2023; 29(8): 2133–2141.
3. Lordick F, Thuss-Patience P, Bitzer M, Maurus D, Sahin U, Türeci Ö. Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastro-oesophageal junction cancer. *J Cancer Res Clin Oncol* 2023; 149(9): 5937–5950.
4. Kroese TE, van Hillegersberg R, Schoppmann S, Deseyne PRAJ, Nafteux P, Obermannova R ... Lordick, F et al. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. *Eur J Cancer* 2022; 164: 18–29.

On the occasion of Brno Oncology Days, Prof. Lordick will deliver an invited lectures on the topic “Novel approaches for HER 2 positive and Claudin 18.2 positive upper GI tumours”.



Prof. Michal Mego, MD, DSc

Faculty of Medicine, Comenius University and the National Cancer Institute, Bratislava, Slovakia

BREAKING NEWS IN GENITOURINARY TUMOURS

Friday 03.11.2023, 9:10 a.m., J. Bakeš Hall

Prof. Mego is the Head of the 2nd Oncology Department, Faculty of Medicine, Comenius University and the National Cancer Institute (NOU) since 2017. He has been a head of Translational Research Unit, LFUK and NOU since 2010. From 2007 to 2011, he worked as an Assistant Professor at the 2nd Oncology Clinic of LFUK and NOU and as a Research Assistant at the Institute of Experimental Oncology, Slovak Academy of Sciences under the supervision of Assoc. Prof. RNDr. Vladimír Zajac, PhD from 1995 to 2001. His main research areas are testicular germ cell tumors, circulating tumor cells and probiotics.

In 2020 he received DSc (Doctor of Science) for his thesis “Clinical and biological value of circulating tumor cells in breast cancer”. In 2014, he was a Visiting Associate Professor and in 2008–2009 visiting Research Scholar at the University of Texas, MD Anderson Cancer Center, Houston. He studied at the Vienna School of Clinical Research (VSCR) and the Vienna Medical University from 2004 till 2007. He graduated at the VSCR and obtained a Diploma in Clinical Research in 2007. In 2007, he completed an internship at the ESMO TRU visit in Vall d’Hebron, Barcelona, Spain. His PhD thesis, entitled “Possibilities of Application of Probiotics in Oncology”, was the result of work at the Institute of Experimental Oncology, Slovak Academy of Sciences from 2001 to 2006. He has been board certified in Clinical Oncology at the Slovak Medical University in Bratislava in 2006. He has gained the ESMO Certificate in Clinical Oncology at the ESMO Conference in Paris in 2005. He attended the 8th FESC-AACR-ASCO Workshop in Switzerland in “Clinical Research Methods” in 2006.

He is the author of two patents of novel methods for detecting circulating tumor cells in the blood. Dr. Mego is a member of several medical societies including Union for International Cancer Control fellows society, American Association for Cancer Research, European Society of Medical Oncology, Slovak Cancer Society, Slovak Medical Society. He is a member of many Editorial Boards. Dr. Mego is a first author or co-author of more than 400 articles including more than 70 peer-reviewed articles.

Selected recent papers:

1. Chovanec M, Kalavska K, Obertova J, Palacka P, Rejlekova K ... Mego M. Cognitive impairment and biomarkers of gut microbial translocation in testicular germ cell tumor survivors. *Front Oncol* 2023; 13: 1146032.
2. Palacka P, Kucharská J, Obertová J, Rejleková K, Slopovský J, Mego M et al. Changes in CoQ10/Lipids Ratio, Oxidative Stress, and Coenzyme Q10 during First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma (mUC). *Int J Mol Sci* 2022; 23(21): 13123.
3. Lesko P, Chovanec M, Mego M. Biomarkers of disease recurrence in stage I testicular germ cell tumours. *Nat Rev Urol* 2022; 19(11): 637–658.

On the occasion of Brno Oncology Days, Prof. Mego will deliver an invited lecture on the topic “Breaking news in genitourinary tumours”.



Prof. Csaba Polgár, MD, PhD, DSc

National Institute of Oncology, Budapest, Hungary

ACCELERATED PARTIAL BREAST IRRADIATION USING INTERSTITIAL MULTICATHETER BRACHYTHERAPY COMPARED WITH WHOLE-BREAST IRRADIATION FOR EARLY BREAST CANCER – 10-YEAR RESULTS OF THE GEC-ESTRO PHASE 3, NON-INFERIORITY TRIAL

Thursday 02.11.2023, 10:30 a.m., J. Bakeš Hall

Prof. Dr. Csaba Polgár is the General Director of the National Institute of Oncology (NIO), Hungary. Prior to his appointment as Director General in 2018, he was the Head of the Center of Radiotherapy at the NIO, where he has been practicing as a radiation oncologist for over two decades. His main research activity is focused on the radiotherapy of breast carcinoma, furthermore he was one of the pioneers implementing the new treatment paradigm of accelerated partial breast irradiation (APBI) in the management of early-stage breast cancer.

Based on his scientific work in the field of breast cancer radiotherapy and brachytherapy he became an internationally recognized expert.

He is a university professor and the Chair of the Department of Oncology of Semmelweis University in Budapest and frequently speaks at national and international conferences. Professor Polgár also holds prominent positions in both national and international professional societies. He served as the president of the GEC-ESTRO Breast Cancer Working Group between 2009–2013, and has been the member of the GEC-ESTRO Committee since 2017. He has been serving as the president of the Hungarian Society of Oncologists between 2021 and 2023.

Prof. Dr. Polgár has authored and co-authored more than 200 peer-reviewed articles and 32 book chapters.

Selected recent papers:

1. Strnad V, Polgár C, Ott OJ, et al. Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. *Lancet Oncol* 2023; 24(3): 262–272.

2. Schäfer R, Strnad V, Polgár C, et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. *Lancet Oncol* 2018; 19(6): 834–844.

3. Polgár C, Ott OJ, Hildebrandt G, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. *Lancet Oncol.* 2017; 18(2): 259–268.

4. Strnad V, Uter W, Polgár C. Partial breast irradiation and the GEC-ESTRO trial - Authors' reply. *Lancet* 2016; 387(10029): 1718–1719.

5. Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. *Lancet* 2016; 387(10015): 229–238.

On the occasion of Brno Oncology Days, Prof. Polgár will deliver an invited lecture on the topic “Accelerated partial breast irradiation using interstitial multicatheter brachytherapy compared with whole-breast irradiation for early breast cancer – 10-year results of the GEC-ESTRO phase 3, non-inferiority trial”.



Assoc. Prof. Gerald Prager, MD

Comprehensive Cancer Center Vienna, Austria

UPDATE ON THE TREATMENT OF PANCREATIC CANCER

Friday 03.11.2023, 11:20 a.m., J. Bakeš Hall

Dr. Gerald Prager is an Associate Professor of Medicine Board Certified for Internal Medicine and Board Certified for Hematology and Medical Oncology. After he graduated from the Medical School of the University of Vienna (MUV, Austria), he completed postdoctoral training at the University of California, San Diego (UCSD, USA). He was a Visiting Professor at the Norris Cancer Center, University of Southern California (USC) in Los Angeles (USA) in 2011.

In 2012 Dr. Prager became an Associate Professor at the Medical University of Vienna. Currently, Dr. Prager is Director of the Gastrointestinal Cancer Program of the Department of Medical Oncology at the Medical University of Vienna and Comprehensive Cancer Center Vienna. Furthermore, he leads the Unit for Precision Medicine in Cancer.

The main research interest of Dr. Prager's lab is on (tumor-) angiogenesis via regulation of cell survival and migration by cell/extracellular-matrix interaction. His work is honored by 20 international awards and has resulted in publications in international highly renowned journals. Dr. Prager is a member of the Scientific Committee of the European Society of Medical Oncology (ESMO).

Selected recent papers:

1. Thaler J, Prager G, Pabinger I, Ay C. Plasma Clot Properties in Patients with Pancreatic Cancer. *Cancers (Basel)* 2023; 15(16): 4030.
2. Taïeb J, Sayah L, Heinrich K, Kunzmann V, Boileve A, Cirkel G, Lonardi S, Chibaudel B, Turpin A, Beller T, Hautefeuille V, Vivaldi C, Mazard T, Bauguion L, Niger M, Prager GW, Coutzac C, Benedikt Westphalen C, Auclin E, Pilla L. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. *Eur J Cancer* 2023; 188: 90–97.
3. Bianconi D, Fabian E, Herac M, Kieler M, Thaler J, Prager G, Unsel M. Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior. *J Cancer* 2022; 13(7): 2271–2280.

On the occasion of Brno Oncology Days, Assoc. Prof. Prager will deliver an invited lecture on the topic "Update on the treatment of pancreatic cancer".



Prof. Rafal Tarnawski, MD, PhD

Radiotherapy and Chemotherapy Clinic, Center of Oncology MSC Institute Branch Gliwice, Poland

RECENT ADVANCES IN TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER (LACC)

Friday 03.11.2023, 9:45 a.m., J. Bakeš Hall

Dr. Tarnawski is a Full Professor of Medicine at MSC National Research Institute of Oncology branch in Gliwice. He is the Head of 3rd Radiotherapy and Chemotherapy Clinic. He was a coordinator of big interinstitutional translational research study "Molecular Diagnostics and Imaging in Individualized Therapy for Breast, Thyroid and Prostate Cancer" (MILESTONE) funded by the National Polish Government Agency.

He is PI in many clinical sponsored and academic. He published several articles on advanced radiotherapy techniques, chemoradiotherapy for cervical cancer, immunotherapy for gynecological cancers.

Selected recent papers:

1. Orski M, Tarnawski R, Wylęgała E, Tarnawska D. The Impact of Robotic Fractionated Radiotherapy for Benign Tumors of Paracellar Region on the Eye Structure and Function. *J Clin Med* 2023; 12(2): 404.
2. Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, et al; Study 309–KEYNOTE-775 Investigators. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. *N Engl J Med* 2022; 386(5): 437–448.
3. Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisianskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matej-

czyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Survival with Cemiplimab in Recurrent Cervical Cancer. *N Engl J Med* 2022; 386(6): 544–555.

4. Williamson CW, Sirák I, Xu R, Portelance L, Wei L, Tarnawski R, et al. Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial. *Int J Radiat Oncol Biol Phys* 2022; 112(1): 169–178.

5. Marth C, Tarnawski R, Tyulyandina A, Pignata S, Gilbert L, et al. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. *Int J Gynecol Cancer* 2022; 32(1): 93–100.

6. Mayadev JS, Ke G, Mahantshetty U, Pereira MD, Tarnawski R, Toita T. Global challenges of radiotherapy for the treatment of locally advanced cervical cancer. *Int J Gynecol Cancer*. 2022; 32(3): 436–445.

On the occasion of Brno Oncology Days, Prof. Tarnawski will deliver an invited lecture on the topic "Recent advances in treatment of locally advanced cervical cancer (LACC)".



Eva Vegh, MD, MBA

South-Pest Medical Centre, Szent Laszlo Hospital, Budapest, Hungary

NEW TRENDS IN THE TREATMENT OF HORMONE RECEPTOR-POSITIVE BREAST CANCER

Thursday 02.11.2023, 2:20 p.m., J. Bakeš Hall

Dr. Eva Vegh boasts over three decades of dedicated experience in the dynamic field of clinical oncology. A highly qualified physician with expertise spanning internal medicine, clinical oncology, clinical pharmacology, and specialized training in palliative care.

Dr. Vegh commenced her illustrious journey in the medical field after graduating from Szeged (Szentgyörgyi) Medical University, marking the beginning of an impressive career. In 1988, she embarked on her professional voyage at the prestigious National Institute of Oncology, specializing in the Department of Chemotherapy.

Over the years, Dr. Vegh has become an integral part of the esteemed medical community. Since 2003, she has been an invaluable asset to the Szent Laszlo Hospital, now recognized as the Southern Pest Medical Center. Her commitment to the institution has been unwavering, with a noteworthy period of full-time service from 2003 to 2007, followed by part-time engagement, and her return to full-time responsibilities in 2017.

During her tenure from 2007 to 2017, Dr. Vegh excelled as a cancer specialist physician, actively contributing to both inpatient and outpatient services of the department. Her extensive bedside experience in oncology proved invaluable, and she played a pivotal role in diverse Phase II-III-IV studies and non-interventional trials.

In addition to her clinical expertise, Dr. Vegh possesses a unique background in the pharmaceutical industry. Her exceptional contributions extend to her role as the founder and owner of Ominis Research, a Hungarian pharmaceutical company distinguished for its comprehensive services, including Clinical Research Organization (CRO), site management, and pharmacovigilance activities.

Selected paper:

Gyöngyösi B, Végh É, Járay B, Székely E, Fassan M, Bodoky G, Schaff Z, Kiss A. Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma. *J Histochem Cytochem* 2014; 62(8): 547–55.

On the occasion of Brno Oncology Days, Dr. Vegh will deliver an invited lecture on the topic “New trends in the treatment of hormone receptor-positive breast cancer”.



Christoph Benedikt Westphalen, MD

Comprehensive Cancer Centre, University Munich, Germany

INTEGRATIVE PRECISION ONCOLOGY – BUILDING SUSTAINABLE STRUCTURES FOR THE FUTURE

Thursday 02.11.2023, 4:05 p.m., J. Bakeš Hall

Benedikt Westphalen studied Medicine and Molecular Biology in Hamburg, Philadelphia, New York, and Bern. After graduating medical school, he started training in Internal Medicine at the University of Hamburg. In 2010, Dr. Westphalen joined the laboratory of Timothy C. Wang at Columbia University in New York City as a postdoctoral fellow. His studies were focused on cellular plasticity and the origins of gastrointestinal malignancies. After his postdoctoral training, he joined the department of hematology and oncology at the University of Munich, where he has focused on clinical and translational research in gastrointestinal cancers with a focus on pancreatic cancer and rare cancers.

Since 2017 he heads precision oncology programme at the Comprehensive Cancer Center at University of Munich, Germany. Since 2021, he represents the CCC Munich within the European Reference Network for rare cancers. He has received research support from the German Research Foundation, the Universities of Hamburg and Munich, the German Cancer Consortium, the German Cancer Aid and young investigator awards from the AACR and GRG/AGA and serves as principal investigator and co-investigator on numerous clinical trials. Dr Westphalen has authored and co-authored more than one hundred research papers.

Dr. Westphalen joined ESMO in 2017 and was a participant in the “ESMO Leaders Generation Programme” in 2018. He joined the ESMO Translational Research and Precision Medicine Working Group as well as the ESMO GI faculty Group in 2019. He currently serves as an officer for the German Cancer Aid (Deutsche Krebshilfe) and the Arbeitsgemeinschaft Internistische Onkologie (AIO). In 2022, Dr. Westphalen was elected to join the EU Commission Mission expert group: Mission Board for Cancer.

Selected recent papers:

1. Heinrich K, Miller-Phillips L, Ziemann F, Hasselmann K, Ruhlmann K ... Westphalen CB. Lessons learned: the first consecutive 1000 patients of the CCCMunich (LMU) Molecular Tumor Board. *J Cancer Res Clin Oncol* 2023; 149(5): 1905–1915.
2. Westphalen CB, Fine, Andre F, Ganesan S, Heinemann V et al. Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score. *Clin Cancer Res* 2022; 28(7): 1412–1421.
3. Mateo J, Steuten L, Aftimos P, Andre F, Davies M ... Westphalen CB, Voest E. Delivering precision oncology to patients with cancer. *Nat Med* 2022; 28(4): 658–665.
4. Westphalen CB, Krebs MG, Le Tourneau C, Sokol ES, Maund SL et al. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. *NPJ Precis Oncol* 2021; 5(1): 69.
5. Westphalen BC, Bokemeyer C, Buttner R, Frohling S, Gaidzik VI et al. Working Group Molecular, and Therapy. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’. *Eur J Cancer* 2020; 135: 1–7.

On the occasion of Brno Oncology Days, Dr. Westphalen will deliver an invited lecture on the topic “Integrative precision oncology – building sustainable structures for the future”.



Prof. Ya-Jung Cheng

Department of Anesthesiology, National Taiwan University Medical School, Taiwan

ROLE OF ANAESTHESIOLOGY IN LUNG CANCER PROGRAMME IN NATIONAL TAIWAN UNIVERSITY CANCER CENTER

Thursday 02.11.2023, 9:18 a.m., J. Bakeš Hall

Ya-Jung Cheng is a prominent figure in the field of anesthesiology, currently holding the position of Chair in the Department of Anesthesiology at the National Taiwan University Cancer Center since November 2019. She has been a Professor in the Department of Anesthesiology at National Taiwan University Medical School since 2018. Her career at National Taiwan University includes serving as Chair of the Department of Anesthesiology from 2013 to 2019, and she became an Associate Professor in the Department of Anesthesiology at National Taiwan University Medical School in 2012. Cheng's extensive expertise includes directorship of cardiothoracic anesthesiology since 2006, and she has been associated with the Department of Anesthesiology at National Taiwan University since 1993.

Cheng's educational background includes a medical doctor degree from Taipei Medical College in 1987 and a PhD. in Physiology from National Taiwan University in 2002.

Her research focuses on various aspects of anesthesiology, including precise anesthesia, non-intubated bronchoscopic interventions, non-intubated thoracoscopic surgery, fluid therapy and its impact on anesthesia and surgical outcomes, perioperative management in thoracoscopic surgery, and pulmonary complications of transplantation.

Selected recent papers:

1. Lin WY, Lin FS, Shih CC, Sung YJ, Chen AY, Piao YC, Chen JS, Cheng YJ. Comparisons on the intraoperative desaturation and postoperative outcomes in non-intubated video-assisted thoracic surgery with supraglottic airway devices or high-flow nasal oxygen: A retrospective study. *J Formos Med Assoc* 2023; 122(4): 309–316.
2. Yie JC, Lin CK, Shih CC, Li YT, Lin WY, Cheng YJ. Nonintubated bronchoscopic interventions with high-flow nasal oxygen: A retrospective observational study. *Medicine (Baltimore)* 2022; 101(22): e29221.
3. Lai CJ, Shih CC, Huang HH, Chien MH, Wu MS, Cheng YJ. Detecting Volemic, Cardiac, and Autonomic Responses From Hypervolemia to Normovolemia via Non-Invasive ClearSight Hemodynamic Monitoring During Hemodialysis: An Observational Investigation. *Front Physiol* 2022; 13: 775631.

On the occasion of Brno Oncology Days, Prof. Cheng will deliver an invited lecture on the topic "Role of anaesthesiology in lung cancer programme in National Taiwan University Cancer Center".



Assoc. Prof. József Furák MD, PhD

Department of Thoracic Surgery, University of Szeged, Hungary

SPONTANEOUS VENTILATION THORACIC SURGERY, EUROPEAN VIEW

Thursday 02.11.2023, 9:40 a.m., J. Bakeš Hall

Dr. József Furák, currently serving as the Head of the Department of Thoracic Surgery at the University of Szeged in Hungary since 2005, has a distinguished career.

He began his journey at the University of Szeged in 1989, transitioning from the Department of Traumatology to Surgery, where he has been since 1992. Graduating in medicine in 1989, he obtained specialist qualifications in Surgery (1994) and Thoracic Surgery (1997). Dr. Furák also achieved the Specialist's Exam of the European Board of Thoracic and Cardiovascular Surgeons in 1999. His educational journey continued with a Ph.D. in 2003 and habilitation in 2016. Notably, he pursued postgraduate training worldwide, mastering VATS surgery and lung transplantation. Proficient in Hungarian, English, and German, he has held leadership roles in professional organizations and earned awards for his contributions, including the prestigious Greek Pioneers' Prize in 2018.

Dr. Furák is a respected figure in the field of thoracic surgery, known for his dedication and excellence in both national and international contexts.

Selected recent papers:

1. Furak J, Szabo Z. Spontaneous ventilation combined with double lumen tube intubation in thoracic surgery. *Gen Thorac Cardiovasc Surg* 2021; 69: 976–982
2. Furak J, Paroczai D, Burian K et al. Oncological advantage of non-intubated thoracic surgery: Better compliance of adjuvant treatment after lung lobectomy. *Thorac Cancer* 2020; 11(11): 3309–3316.
3. Szanto Z, Furak J, Falkoz PE, Brunelli A. A country wide adaptation of the European Society of Thoracic Surgeons lung cancer core database: the Hungarian model. *J Thor Dis* 2018; 10(S29): S3467–S3471.

On the occasion of Brno Oncology Days, Assoc. Prof. Furák will deliver an invited lecture on the topic "Spontaneous ventilation thoracic surgery, European view".



Prof. Mong-Wei Lin, MD, PhD

Department of Surgery, National Taiwan University Hospital, Taiwan

ROLE OF SURGERY IN LUNG CANCER PROGRAMME AT NTU CANCER CENTER

Thursday 02.11.2023, 9:29 a.m., J. Bakeš Hall

Mong-Wei Lin, M.D., Ph.D., is a distinguished figure in the field of thoracic surgery, currently serving as a Professor in the Department of Surgery at the College of Medicine, National Taiwan University. He is also the Chief of the Division of Thoracic Surgery at National Taiwan University Hospital and holds directorship positions in prestigious medical associations such as the Taiwan Society of Thoracic Surgeons and the Taiwan Association of Thoracic and Cardiovascular Surgery.

Lin's extensive medical journey began with a medical degree and a Ph.D. from National Taiwan University, where he conducted research on the clinicopathology and genetic profile of multiple adenocarcinomas. He has contributed significantly to academia, publishing numerous articles and delivering over 500 invited lectures.

Lin's professional experience includes roles as an attending physician, chief of ward, and director across various medical institutions in Taiwan and internationally, including Keio University Hospital in Tokyo and Massachusetts General Hospital in Boston. He holds several medical licenses and certifications, including Board of Surgery, Board of Thoracic Surgery, and Board of Robotic Surgery in Taiwan. Lin is an active member of several medical societies, including the International Association for the Study of Lung Cancer and the Asian Pacific Society of Respiriology. He has received numerous awards and honors for his contributions to medical education, research, and clinical practice, including Teaching Excellence Awards and President Research Awards.

Selected recent papers:

1. Lin MW, Yu SL, Hsu YC, Chen YM, Chen JS, et al. Salvage surgery for advanced lung adenocarcinoma after epidermal growth factor receptor tyrosine kinase inhibitor treatment. *Ann Thor Surg* 2023; 116(1): 111–119.
2. Chuang JH, Chen PH, Lu TP, Hung WT, Liao HC, Tsai TM, Lin MW, Chen KC, Hsu HH, Chen JS. Uniportal versus multiportal non-intubated thoracoscopic anatomical resection for lung cancer: a propensity-matched analysis. *J Formos Med Assoc* 2023; 122(9): 947–954.
3. Mathey-Andrews C, Potter AL, Venkateswaran S, Deng JZ, Alvilal AJ, Lin MW, Auchincloss HG, Jeffrey Yang CF. Wedge resection versus segmentectomy for older patients with stage ia non-small-cell lung cancer. *J Surg Res* 2023; 283: 1133–1144.
4. Chen LW, Lin MW, Hsieh MS, Yang SM, Wang HJ, Chen YC et al. Radiomic values from high-grade subtypes to predict spread through air spaces in lung adenocarcinoma. *Ann Thor Surg* 2022; 114(3): 999–1006.

On the occasion of Brno Oncology Days, Prof. Lin will deliver an invited lecture on the topic "Role of surgery in lung cancer programme at NTU Cancer Center".



Ramón Rami-Porta, MD, PhD

Department of Thoracic Surgery, Hospital Universitari Mutua Terrassa, Barcelona, Spain

THE IASLC LUNG CANCER STAGING PROJECT – TOWARDS THE 9TH EDITION OF THE TNM CLASSIFICATION
Thursday 02.11.2023, 9:51 a.m., J. Bakeš Hall

Ramón Rami-Porta is a renowned thoracic surgeon based in Terrassa, Barcelona, Spain. He completed his medical education at the University of Barcelona in 1980 and subsequently pursued a residency in Thoracic Surgery at the Fundación 'Jiménez Díaz', Autonomous University of Madrid, becoming Board Certified in Thoracic Surgery.

In 1986, he earned a doctorate (PhD degree) from the Autonomous University of Madrid. Rami-Porta is also Board Certified in Thoracic and Cardiovascular Surgery by the European Union of Medical Specialists. He has been an active member of various scientific societies, including the Spanish Society of Pneumology and Thoracic Surgery, International Association for the Study of Lung Cancer, European Society of Thoracic Surgeons, and more.

Rami-Porta has made significant contributions to the field with over 170 articles published in national and international journals and has delivered over 500 invited lectures.

Currently, he serves as the Clinical Chief of the Department of Thoracic Surgery at Hospital Universitari Mutua Terrassa.

Selected recent papers:

1. Osarogiagbon RU, Van Schil P, Giroux DJ, Lim E, Putora PM, Lievens Y, Rami-Porta R, Rusch VW, Asamura H, Huang J; Members of the N-Descriptors Subcommittee. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Overview of Challenges and Opportunities in Revising the Nodal Classification of Lung Cancer. *J Thorac Oncol* 2023; 18(4): 410–418.

2. Sanz-Santos J, Almagro P, Malik K, Martinez-Cambor P, Caro C, Rami-Porta R. Confirmatory Mediastinoscopy after Negative Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Mediastinal Staging of Lung Cancer: Systematic Review and Meta-analysis. *Ann Am Thorac Soc* 2022; 19(9): 1581–1590.

3. Obiols C, Call S, Rami-Porta R, Jaén Á, Gómez de Antonio D, Crowley Carrasco S, Royo-Crespo Í, Embún R. Radicality of lymphadenectomy in lung cancer resections by thoracotomy and video-assisted thoracoscopic approach: A prospective, multicentre and propensity-score adjusted study. *Lung Cancer* 2022; 165: 63–70.

On the occasion of Brno Oncology Days, Dr. Rami-Porta will deliver an invited lecture on the topic “The IASLC lung cancer staging project – towards the 9th edition of the TNM Classification”.



Zsolt Szabo MD, PhD

University of Szeged and Tritonlife Szeged Private Hospital, Hungary

SPONTANEOUS VENTILATION WITH DOUBLE LUMEN TUBE INTUBATION IS MISSION IMPOSSIBLE! OR IS IT STILL POSSIBLE?

Thursday 02.11.2023, 9:07 a.m., J. Bakeš Hall

Zsolt Szabo, MD, PhD, is a highly skilled anesthesiologist and intensive care specialist with an impressive background. He previously served as the Deputy Director of the Department of Anesthesiology and Intensive Therapy at the University of Szeged, Hungary. Currently, he holds the position of Deputy Medical Director at Tritonlife Szeged Private Hospital in Szeged, Hungary. Additionally, he is a valuable team member of the Experimental Surgery team at the Institute of Surgical Research, University of Szeged. Szabo also plays a crucial role as a PhD Supervisor at the Multidisciplinary Doctoral School, University of Szeged.

Dr. Szabo's clinical interests revolve around the development of minimally invasive anesthesiological techniques for both benign and malignant thoracic surgical procedures involving the lung and mediastinum. His research activities primarily focus on optimizing short-term and long-term patient outcomes following thoracic surgical operations, with a particular emphasis on anesthesiological considerations. He boasts a notable portfolio of more than 20 publications, encompassing minimally invasive thoracic surgical techniques and the evaluation of outcomes related to the treatment of thoracic malignancies.

Selected recent papers:

1. Géczi T, Simonka Z, Lantos J, Wetzel M, Szabó Z, Lázár G, Furák J. Near-infrared fluorescence guided surgery: State of the evidence from a health technology assessment perspective. *Front Surg* 2022; 9: 919739.
2. Furák J, Németh T, Lantos J, Fabó C, Géczi T, Zombori-Tóth N, Paróczai D, Szántó Z, Szabó Z. Perioperative Systemic Inflammation in Lung Cancer Surgery. *Front Surg* 2022; 9: 883322.
3. Szabo Z, Fabo C, Oszlanyi A, Hawchar F, Géczi T, Lantos J, Furák J. Anesthetic (r)evolution from the conventional concept to the minimally invasive techniques in thoracic surgery-narrative review. *J Thorac Dis* 2022; 14(8): 3045–3060.

On the occasion of Brno Oncology Days, Dr. Szabo will deliver an invited lecture on the topic "Spontaneous ventilation with double lumen tube intubation is mission impossible! Or is it still possible?".



Prof. Marcin Zieliński MD, PhD

Department of Thoracic Surgery, Pulmonary Hospital, Zakopane, Poland

TRANSCERVICAL LOBECTOMY

Thursday 02.11.2023, 8:56 a.m., J. Bakeš Hall

Marcin Zieliński, MD, PhD, is an accomplished Thoracic Surgeon and General Surgeon with an impressive background. He obtained his M.B. from the Medical Academy in Warsaw in 1983 and later became a Specialist in Thoracic Surgery in 1990 and a Specialist in General Surgery in 1996.

Dr. Zieliński has achieved significant scientific degrees, including a doctorate in 1994, habilitation in 2006, and the title of professor in 2020. His contributions to the field of thoracic surgery are remarkable. He has introduced innovative surgical techniques, such as Transcervical-Subxiphoid-VATS Maximal Thymectomy, VATS Resternotomy for rethymectomy, Transcervical Extended Mediastinal Lymphadenectomy (TEMLA), Transcervical Pulmonary Lobectomy, and Subxiphoid-Right VATS Thymectomy and Rethymectomy. Currently, his main focus lies in refining the techniques of transcervical and subxiphoid approaches for pulmonary resections and mediastinal procedures.

Dr. Zieliński has an extensive publication record, including a book titled „Transcervical Approach in Thoracic Surgery“, co-edited with Rami-Porta and published by Springer in 2014.

He is an active member of several prestigious organizations, including the European Society of Thoracic Surgeons (ESTS), European Association for Cardio-Thoracic Surgery (EACTS), International Association for the Study of Lung Cancer (IASLC), Society of Polish Surgeons, and the American Association for Thoracic Surgery (AATS).

Among his many accomplishments, Dr. Zieliński received the Tsuguo Naruke Lectureship Award in 2011 during the World Congress of Lung Cancer in Amsterdam. He has also contributed to various committees, including ESTS working groups, the Thoracic Domain of EACTS, the EACTS thymic working group, and the IASLC Staging Committee.

Selected recent papers:

1. Piwkowski C, Gabryel P, Campisi A, Orłowski TM, Zieliński M et al; Polish National Lung Cancer Registry. Ninety-Day Mortality of Thoracoscopic vs Open Lobectomy: A Large Multicenter Cohort Study. *Ann Thorac Surg* 2023; 115(3): 693–699.
2. Orzechowski S, Gnass M, Czyżewski D, Wojtacha J, Sudoł B ... Zieliński M, Szlubowski A. Ultrasound predictors of left adrenal metastasis in patients with lung cancer: a comparison of computed tomography, positron emission tomography-computed tomography, and endoscopic ultrasound using ultrasound bronchoscope. *Pol Arch Intern Med* 2022; 132(1): 16127.

On the occasion of Brno Oncology Days, Prof. Zieliński will deliver an invited lecture on the topic “Transcervical lobectomy”.



Alied van der Aa-van Delden

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

FROM A DANGEROUS LAKE TO A RIPPLING STREAM – THE PSYCHOSOCIAL IMPACT OF CHILDHOOD CANCER ON ADULT SURVIVORS

Friday 03.11.2023, 8:35 a.m., R. Werner Hall

Alied van der Aa-van Delden is a Dutch Nationality Health Psychologist with a passion for helping individuals cope with the challenges of illness.

She currently serves as a Licensed Health Psychologist at the Outpatient Clinic for the Late Effects of Childhood Cancer at the Princess Máxima Center for Pediatric Oncology since April 2021. Prior to this, she worked as a Licensed Health Psychologist at the Comprehensive Cancer Center of Maastricht University Medical Center for nearly six years. Her experience also includes being a Psychologist at the Oncology Center of Maastricht University Medical Center.

Alied's passion for improving the well-being of those facing cancer is highlighted by her role as Project Manager and Psychologist at Toon Hermanshuis Maastricht, a Cancer support center. Before specializing in health psychology, she contributed as a Project Team Member and Health Scientist in developing a Computer Reminder System to Improve Prescribing Behavior of General Practitioners at Maastricht University Medical Center. Her academic journey includes a Postmaster degree in Health Psychology from RINO Zuid and a Master of Arts in Counseling from Covenant Theological Seminary in the United States. She obtained a Master's degree in Clinical Psychology from Utrecht University and a Master's in Health Sciences and Mental Health from Maastricht University.

Alied has continued her professional development through various courses such as EMDR Basic Certificate for Health Psychologists, ACT (Acceptance and Commitment Therapy) for beginners, CBT for Chronic Fatigue in Cancer Patients, and training in Acceptance and Commitment Therapy, among others. Her extensive education and diverse experience make her a dedicated and well-rounded professional in the field of health psychology.

Selected recent papers:

1. Maas A, Maurice-Stam H, van der Aa-van Delden AM et al. Dutch LATER study group. Positive and negative survivor-specific psychosocial consequences of childhood cancer: the DCCSS-LATER 2 psycho-oncology study. *J Cancer Surviv* 2023; May 11.
2. Maas A, Maurice-Stam H, Kremer LCM, van der Aa-van Delden A et al.; Dutch LATER study group. Psychosocial outcomes in long-term Dutch adult survivors of childhood cancer: The DCCSS-LATER 2 psycho-oncology study. *Cancer* 2023; 129(16): 2553–2567.
3. van Gorp M, Joosten MMH, Maas A, Drenth BL, van der Aa-van Delden A et al.; Dutch LATER study group. Psychosocial functioning of parents of Dutch long-term survivors of childhood cancer. *Psychooncology* 2023; 32(2): 283–294.

On the occasion of Brno Oncology Days, A. van der Aa-van Delden will deliver an invited lectures on the topic "From a dangerous lake to a rippling stream – the psychosocial impact of childhood cancer on adult survivors".



Trish Bartley

Specialist in Mindfulness and Mindfulness-Based Cognitive Therapy for Cancer, Bicester, England

WHAT DOES MINDFULNESS OFFER PEOPLE WITH CANCER?

Thursday 02.11.2023, 12:05 p.m., J. Bakeš Hall

MINDFULNESS AND CANCER: A KINDLY ACCESSIBLE RESOURCE (Experiential Workshop)

Thursday 02.11.2023, 1.00 p.m., V. Morávek Hall

Trish Bartley has been involved in mindfulness-based teaching since the beginnings of Mindfulness-based Cognitive Therapy (MBCT). She started teaching mindfulness in hospital to people with cancer in 2001, supported by Mark Williams and John Teasdale (two MBCT founders). She adapted the programme and published it in 2012 and has since taught MBCT-Ca in groups to several hundred people with cancer. She currently works online with people with advanced cancer and trains mindfulness teachers in the UK, Europe and sometimes further afield in Africa and Asia.

Trish has a background in development and participatory process work. She has written four books including Mindfulness-Based Cognitive Therapy for Cancer (Bartley, 2012) a handbook for mindfulness teachers; Mindfulness: A Kindly Approach to Being with Cancer (Bartley, 2017) a book for people with cancer themselves; and a new book Teaching Mindfulness-Based Groups (Bartley & Griffith, 2022).

Selected publications:

1. Bartley, T. Mindfulness-based cognitive therapy for cancer: Gently turning towards. Wiley-Blackwell 2012.
2. Bartley, T. Mindfulness: A kindly approach to being with cancer. Wiley-Blackwell 2017.
3. Bartley, T. & Griffith, G. Teaching Mindfulness-Based Groups. Pavilion Publishing and Media 2022.

On the occasion of Brno Oncology Days, T. Bartley will deliver an invited lecture on the topic “What does mindfulness offer people with cancer? A keynote presentation based on the principles of Mindfulness-Based Cognitive Therapy for Cancer (MBCT-Ca)” and will conduct a workshop “Mindfulness and Cancer: A kindly accessible resource”.

Diagnostic and treatment centres in MMCI

The MMCI has **22 diagnostic and treatment centres**, which focus on different cancer types, treatment procedures or supportive care services. Treatment centres deliver comprehensive cancer care based on interdisciplinary teamwork of specialist physicians and other non-medical healthcare professionals.

The concept of treatment centres enables us to provide **high-quality medical services** to MMCI patients and to share our expertise with other healthcare institutions within the region. Furthermore, MMCI provides **access to the most innovative diagnostics** and cancer treatment options including **robotic surgery, theranostics, precision oncology and radiotherapy**.

Breast Cancer Centre

Centres for Gastrointestinal tumors

- Centre for Oesophageal and Gastric Cancer
- Colon Cancer Centre
- Centre for Liver and Biliary Tract Cancer
- Centre for Pancreatic Cancer

Centres for Urologic tumors

- Prostate Cancer Centre
- Kidney and Urinary Tract Cancer Centre
- Testicular Cancer Centre

Centres for Gynecologic tumors

- Centre for Ovarian, Tubal and Peritoneal Cancers
- Centre for Uterine, Cervical and Vulvar Cancers

Centre for Lung and Pleural Cancer

Centre for Skin Cancer and Melanoma

Centre for Brain and Spinal Cord Tumours

Head and Neck Cancer Centre

Sarcoma centre

Centre for Neuroendocrine Tumours

Thyroid Cancer Centre

Centre for cancer of unknown primary and other rare malignancies

Centre for Precision Oncology

Robotic Surgery Centre

Centre for Palliative Medicine and Pain Management

Centre for cytoreduction and regional chemotherapy



Masaryk Memorial Cancer Institute



Masaryk Memorial Cancer Institute (MMCI) is **the largest cancer centre in the Czech Republic** in terms of the number of primarily treated adult patients with solid tumors and the provision of preventive cancer care. **Almost 5 000 newly diagnosed cancer patients** start treatment in MMCI every year. MMCI currently plays the role of the National cancer centre in the network of Czech Comprehensive Cancer Centres.

MMCI is an internationally recognized Institute, an accredited member of **the Organisation of European Cancer Institutes (OECI)** and **ESMO Designated Centre of Integrated Oncology and Palliative Care**. MMCI is also a member of ERN network for rare adult solid cancers EURACAN and for genetic tumor risk syndromes GENTURIS.

MMCI serves as a national node of the **BBMRI-ERIC** research infrastructure for biobanking and is a partner of Czech Clinical Research Infrastructure Network (CZECRIN).

MMCI is providing **health care services, research and education** in the areas of prevention, diagnosis and treatment of solid tumors. MMCI is affiliated to Masaryk University, within which it cooperates with two other university hospitals: University Hospital Brno and St. Anne's University Hospital. MMCI operates its own facility for basic and translational research called **RECAMO** (Research Centre for Applied Molecular Oncology) and provides full support for **clinical research, including Phase I Clinical Trial Unit**, biobanking and precision oncology programme.

